Top Markets
Coin of the day
Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD
Rangering i aksjer #17261
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Aksjekurs
$0.8502
Sist synkronisert: 2026-09-01
Markedsverdi
$250.47M
Endring (1 dag)
-10.96%
Endring (1 år)
-17.46%
Land
US
Handel Invivyd, Inc. (IVVD)

Kategori

P/S-forhold for Invivyd, Inc. (IVVD)
P/S-forhold per 2026 TTM: 0
Ifølge Invivyd, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Invivyd, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH